

- **Name:** Kyong Hwa Park, MD, PhD
 - **Current Position & Affiliation:** Professor, Oncology/Hematology, Department of internal medicine, College of medicine, Korea University
 - **Country:** Korea
-

• **Educational Background:**

2002–2005 Ph. D., Graduate School, Korea University, College of Medicine, Seoul, Korea.

1999–2002: Master's Course. Graduate School of Korea University, Majored in Internal Medicine, Seoul, Korea.

1990–1998: MD, College of Medicine, Korea University, Seoul, Korea

• **Professional Experience:**

2016.2 – 2022.1: Chair, Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital

2014. 3- 2015. 2: Visiting scientist, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.

2013. 3– 2018. 2: Associate professor, Korea University

2009. 3– 2013. 2: Assistant professor, Korea University

2007. 9– 2009. 2: Full time lecturer, Oncology/Hematology, Korea University

2007. 6–2007. 8: Clinical Assistant Professor, Oncology/Hematology, Korea University Anam Hospital

2005. 6–2007. 6: Postdoctoral fellow, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.

2004. 3–2005. 5: Clinical fellowship in Division of Oncology/Hematology, Internal Medicine, Korea University Hospital, Seoul, Korea.

1999. 3–2004. 2: Residency in Internal Medicine, Korea University Hospital, Seoul, Korea.

1998. 3–1999. 2: Rotating Internship, Korea University Hospital, Seoul, Korea.

• **Professional Organizations:**

Member, Korean Society of Medical Oncology

Board member, Korean Cancer Study Group

Chair, Scientific committee, Korean Cancer Association

Member, American Association for Cancer Research

Member, ASCO

Member ESMO

Member, SITC

• Main Scientific Publications:

Park KH et al. ESMO Open 2024. <https://doi.org/10.1016/j.esmoop.2024.102974> Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

Ju Won Kim, Hyo Jin Lee, **Kyong Hwa Park** et al. J Immunother Cancer. 2024; 12(3): e008638. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Ju Won Kim, Ah Reum Lim, **Kyong Hwa Park** et al. BMC Complementary Medicine and Therapies (2024) 24:163 The clinical effect of an electric massage chair on chemotherapy-induced nausea and vomiting in cancer patients: randomized phase II cross-over trial

JW Lee, H Oh, JY Youc, ES Lee, JH Lee, SE Song, NK Lee, SP Jung, JS An, KR Cho, CY Kim, **Kyong Hwa Park**. European Journal of Cancer 191 (2023) 112952 Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy

JH Kang, HJ Lee, j Hong, YH Kim, Disis ML, Gim JA, **Park KH**. J Immunother Cancer. 2022 Sep;10(9):e004702. doi: 10.1136/jitc-2022-004702. Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+breast cancer murine model

Park KH, Choi JY, Lim AR, Kim JW, Choi YJ, S Lee, Kim YH, Sa K. J et al. Cancer Discov (2022) 12 (4): 938–948. Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program

Lim AR, **Park KH** at al. Support Care Cancer . 2022 Jun;30(6):5289-5297. Blood transfusion has an adverse impact on the prognosis of patients receiving chemotherapy for advanced colorectal cancer: experience from a single institution with a patient blood management program